<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ROPIVACAINE HYDROCHLORIDE</span><br/>(ro-piv'i-cane)<br/><span class="topboxtradename">Naropin<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">local anesthetic (ester-type)</span><br/><b>Prototype: </b>Procaine HCl<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL, 5 mg/mL, 7.5 mg/mL, 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Blocks the generation and conduction of nerve impulses, probably by increasing the threshold for electrical excitability.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Local anesthetic action produces loss of sensation and motor activity in areas of the body close to the injection site.</p>
<h1><a name="uses">Uses</a></h1>
<p>Local and regional anesthesia, postoperative pain management, anesthesia/pain management for obstetric procedures.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ropivacaine or any local anesthetic of the amide type; generalized septicemia, inflammation or sepsis
         at the proposed injection site; cerebral spinal diseases (e.g., meningitis); heart block, hypotension, hypertension, GI hemorrhage.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation, debilitated, older adult, or acutely ill patients; arrhythmias, shock.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Surgical Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Epidural</span> 25200 mg (0.51% solution) <span class="rdroute">Nerve block</span> 5250 mg (0.5%, 0.75% solution)<br/><br/><span class="indicationtitle">Labor Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Epidural</span> 2040 mg (0.2% solution)<br/><br/><span class="indicationtitle">Postoperative Pain Management</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Epidural</span> 1220 mg/h (0.2% solution) <span class="rdroute">Infiltration</span> 2200 mg (0.20.5% solution)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intrathecal</span><br/><ul>
<li>Avoid rapid injection of large volumes of ropivacaine. Incremental doses should always be used to achieve the smallest effective
            dose and concentration.
         </li>
<li>Use an infusion concentration of 2 mg/mL (0.2%) for postoperative analgesia.</li>
<li>Do not use disinfecting agents containing heavy metal ions (e.g., mercury, copper, zinc, etc.) on skin insertion site or to
            clean the ropivacaine container top.
         </li>
<li>Discard continuous infusions solution after 24 h; it contains no preservatives.</li>
<li>Store unopened at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Pain, fever, rigors, hypoesthesia. <span class="typehead">CNS:</span> Paresthesia, headache, dizziness, anxiety. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension,</span> bradycardia, hypertension, tachycardia, chest pain, fetal bradycardia. <span class="typehead">GI:</span> Nausea. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Urogenital:</span> Urinary retention, oliguria. <span class="typehead">Hematologic:</span> Anemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive adverse effects with other <span class="classification">local anesthetics</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 130 min (average 1020 min) depending on dose/route of administration. <span class="typehead">Duration:</span> 0.58 h depending on dose/route of administration. <span class="typehead">Distribution:</span> 94% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP1A. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.84.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully cardiovascular and respiratory status throughout treatment period. Assess for hypotension and bradycardia.</li>
<li>Report immediately S&amp;S of CNS stimulation or CNS depression.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician immediately: restlessness, anxiety, tinnitus, blurred vision, tremors.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>